PhytoHealth Corporation announced that New drug in development #1: Anti-osteoporosis Clinical trial for preventing osteoporosis: Trial Title: PH3 for the Prevention of Osteoporosis in Post-menopausal Women in Phase II, Double-Blind, Randomized, and Placebo Controlled Study. Institution: TVGH, CGMH, NTUH and MMH. Trial Update: Phase II clinical study was completed.

The company continues to assess the compatibility of clinical trial regulations between Taiwan and China and to explore clinical trial cooperation possbility in accordance with clinical trials harmonization. Continuous monitoring of species identification and cultivation. The product development has achieved phased results, and will be jointly developed at an appropriate time and after seeking strategic partners.